INSIGHTS ON CLINICAL TRIAL REGULATORY ISSUES

• Under Half Of CTIS Trials Met Results Reporting Requirements

  A first assessment of compliance on EU Clinical Trial Information System (CTIS) found fewer than half of European Phase II–IV drug trials legally required to post results fully complied on time.

• The Regulatory Compass Driving Drug Delivery Innovation

  Regulatory requirements are growing more complex. Discover how strategic planning, regulatory intelligence, and platform approaches can streamline development and approvals.

• MIDBA: A New Regulatory Approach To Clinical Device Bridging

  When devices evolve, evidence expectations can shift. Explore a risk-based clinical bridging approach to support regulatory decisions.

• Matching Pharmacovigilance Methodology To Organizational Scale

  One-size-fits-all doesn't work for safety signal detection. Discover a scalable framework that keeps expert judgment at the center — no matter how large your portfolio grows.

• Clinical Supply Flexibility Where Biotech Programs Need It Most

  8/10/2026

  Flexible clinical development requires scalable infrastructure, strong project management, and global logistics to ensure supply continuity and regulatory compliance.

• Packaging And Labeling Support For A Global Cell Therapy Program

  8/10/2026

  Master complex cell therapy logistics with coordinated depots, purpose-built labeling, and temperature-controlled solutions that protect product integrity.

• Improving Clinical Trial Label Translation Through Centralized Reuse And Control

  8/10/2026

  Eliminate workflow inefficiencies and regulatory risk in global trials with a centralized translation framework and validated phrase library for consistent, cost-effective execution.

• 7 Practical Implications Of ICH E6(R3) For Early-Phase Trial Design

  8/10/2026

  A risk-based quality approach can enhance participant protection, data integrity, and development success through focused oversight, strong governance, and clear documentation.

• Speed Kills: When Timelines Trump Science In Neuropsychiatric Trials

  8/4/2026

  This Bold Conversation brings together experts helping to define the next chapter of psychedelic clinical research to unpack lessons from recent regulatory reviews and explore what clinical teams need now.

REGULATORY MULTIMEDIA

• Speed Kills: When Timelines Trump Science In Neuropsychiatric Trials

  This Bold Conversation brings together experts helping to define the next chapter of psychedelic clinical research to unpack lessons from recent regulatory reviews and explore what clinical teams need now.

• Building the Blueprint: What Psychedelic Trials Need Now

  Discover how leading experts are addressing recent regulatory reviews to shape the next phase of psychedelic clinical research.

• The Evolution Of GLP-1s: Overcoming Clinical Development Challenges

  Explore clinical development trends, recruitment hurdles, study design strategies, and emerging therapies shaping obesity and metabolic disease research.

• Unifying Research - HRPP Vs IRB And Participant Christine

  HRPPs and IRBs play different but connected roles in protecting research participants. Hear expert guidance, firsthand experiences, and questions that can help people make more informed decisions.

• Unifying Research - Research Administration And Participant Caregiver

  Go behind the scenes of cancer clinical trials operations and hear a caregiver’s perspective on supporting a research participant, including the challenges, needs, and opportunities.

• Unifying Research - Research Compliance And Patient Stephanie

  A research compliance leader and a patient advocate explore how ethical oversight, privacy, and the IRB intersect while sharing a personal PMDD journey that shows the potential of participation.

• A More Intuitive IRB Submission Experience

  Gain insight into a more intuitive IRB submission experience that can help reduce friction, improve transparency, and support today’s virtual research workflows.

• Your IRB, Simplified: Fast, Friendly, And Focused

  IRB approval does not have to be defined by delays or confusion. Learn how expert guidance, regulatory support, and modern technology can help research teams move forward with greater efficiency.

• Accelerating Rare Disease Access Through Global Alignment

  Rare disease innovation is accelerating, but fragmented regulations, inconsistent data standards, and limited natural history data can slow progress. Global alignment is key to faster patient access.

• Translating R3 Data Governance And Oversight Into Practice

  Learn how to translate ICH E6(R3) into practice with actionable strategies for proactive risk management, robust data governance, and earlier deviation detection.